Why the study?
Does ticagrelor reduce the incidence of cardiovascular and limb-specific events compared to clopidogrel in patients with symptomatic peripheral artery disease?
Population
13,887 subjects with symptomatic peripheral artery disease (PAD)
Comparison
Ticagrelor 90 mg twice daily vs Clopidogrel 75 mg daily
Design
RCT, 1:1 fashion, double-blind
Follow-up
until at least 1,364 adjudicated primary end points occur
Authors
Loading...
The EUCLID trial is designed to evaluate whether ticagrelor is superior to clopidogrel for preventing major adverse cardiovascular events in patients with symptomatic peripheral artery disease.
Does ticagrelor reduce the incidence of cardiovascular and limb-specific events compared to clopidogrel in patients with symptomatic peripheral artery disease?
The EUCLID trial is designed to evaluate whether ticagrelor is superior to clopidogrel for preventing major adverse cardiovascular events in patients with symptomatic peripheral artery disease.
Berger et al. (2016) studied this question.